Entero Therapeutics, Inc. (ENTO) - Total Assets
Based on the latest financial reports, Entero Therapeutics, Inc. (ENTO) holds total assets worth $135.37 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ENTO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Entero Therapeutics, Inc. - Total Assets Trend (2013–2024)
This chart illustrates how Entero Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Check how high is Entero Therapeutics, Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
Entero Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Entero Therapeutics, Inc.'s total assets of $135.37 Million consist of 97.7% current assets and 2.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.68 Million | 2.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Entero Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Entero Therapeutics, Inc. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entero Therapeutics, Inc.'s current assets represent 97.7% of total assets in 2024, an increase from 93.9% in 2013.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2024, down from 4.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 2.0% of total assets.
Entero Therapeutics, Inc. Competitors by Total Assets
Key competitors of Entero Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Entero Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 5.34 | 0.51 |
| Quick Ratio | 2.62 | 5.34 | 0.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $54.18 Million | $68.15 Million | $-7.68 Million |
Entero Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Entero Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.42 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 1140.8% |
| Total Assets | $85.41 Million |
| Market Capitalization | $9.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Entero Therapeutics, Inc.'s assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Entero Therapeutics, Inc.'s assets grew by 1140.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual total assets of Entero Therapeutics, Inc. from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $85.41 Million | +1140.84% |
| 2023-12-31 | $6.88 Million | +26.54% |
| 2022-12-31 | $5.44 Million | -53.86% |
| 2021-12-31 | $11.79 Million | -8.77% |
| 2020-12-31 | $12.92 Million | +45.16% |
| 2019-12-31 | $8.90 Million | +19.19% |
| 2018-12-31 | $7.47 Million | +14.02% |
| 2017-12-31 | $6.55 Million | -3.01% |
| 2016-12-31 | $6.75 Million | +1.02% |
| 2015-12-31 | $6.69 Million | +1.67% |
| 2014-12-31 | $6.58 Million | +661511.13% |
| 2013-12-31 | $993.90 | -- |
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more